Haemochromatosis: 3. Therapeutic venesection for haemochromatosis

CPD hours: Educational activities: 
1
CPD hours: Measuring outcomes: 
0
CPD hours: Reviewing performance: 
0.5

You need to login to participate in this education.

Please log in, or if you don't already have a free account, register to continue.

This education is accredited: RACGP 2 CPD, ACRRM 1.5 CME PD.

This is one module of the haemochromatosis series of education, which is also available as the 5-hour Accredited CPD Activity Haemochromatosis: Preventing harm caused by iron overload with timely diagnosis and best practice management.

 

In this module, participants will learn about appropriate induction and maintenance venesection schedules for patients with hereditary haemochromatosis, as well as circumstances that warrant referral to a specialist. Participants will also learn how to access the Australian Red Cross Blood Service (ARCBS) High Ferritin app, and how to use it to screen patients for their eligibility to access therapeutic venesection. The module also looks at how to access local alternatives to the ARCBS therapeutic venesection service.

On completion of this education activity participants will be able to:
  • Describe how iron levels are reduced in hereditary haemochromatosis.
  • Describe appropriate induction and maintenance venesection schedules for individuals with hereditary haemochromatosis, and appropriate monitoring during each phase of treatment.
  • List the circumstances where you might refer a patient with hereditary haemochromatosis to a specialist.
  • Access the Australian Red Cross Blood Service (ARCBS) High Ferritin app and screen patients for their eligibility to access therapeutic venesection through this service.
  • Know how to find your local alternatives to the ARCBS therapeutic venesection service.


This activity is sponsored by Haemochromatosis Australia.
Content partners: 
Components
Haemochromatosis: 3. Therapeutic venesection for haemochromatosis - Education
Haemochromatosis: 3. Therapeutic venesection for haemochromatosis - Evaluation